Cargando…

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Dopamine receptor partial agonists (DRPAs; aripiprazole, brexpiprazole, and cariprazine) constitute a novel class of antipsychotics. Although they share a similar mechanism of action, DRPAs differ in their pharmacodynamics, pharmacokinetics, drug interactions, or safety and tolerability. The antipsy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohr, Pavel, Masopust, Jirí, Kopeček, Miloslav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821167/ https://www.ncbi.nlm.nih.gov/pubmed/35145438 http://dx.doi.org/10.3389/fpsyt.2021.781946

Ejemplares similares

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
por: Sumi, Satoko, et al.
Publicado: (2022)

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
por: Mandic-Maravic, Vanja, et al.
Publicado: (2022)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Partial Agonists and Dual Disorders: Focus on Dual Schizophrenia
por: Peris, Lola, et al.
Publicado: (2021)

An Overview of the Association between Schizotypy and Dopamine
por: Mohr, Christine, et al.
Publicado: (2014)

Impairment of Executive Functions Associated With Lower D-Serine Serum Levels in Patients With Schizophrenia
por: Hons, Jaromir, et al.
Publicado: (2021)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series
por: Masopust, Jiri, et al.
Publicado: (2019)

EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive–compulsive disorder (OCD)-like behaviors
por: Youngblood, Beth, et al.
Publicado: (2023)

Editorial: Novel antipsychotics within and beyond clinical trials: The treatment of overlapping psychiatric disorders with D3-D2 partial agonists
por: Németh, György, et al.
Publicado: (2022)

Ghrelin receptor agonist MK0677 and overnight fasting do not rescue deficient fear extinction in 129S1/SvImJ mice
por: Fritz, Eva Maria, et al.
Publicado: (2023)

Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects
por: Silverstone, P. H., et al.
Publicado: (2012)

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
por: Seeman, P
Publicado: (2016)

In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
por: Khroyan, Taline V., et al.
Publicado: (2017)

Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
por: Rampino, Antonio, et al.
Publicado: (2019)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)
por: Ivanov, Stanislav V., et al.
Publicado: (2022)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Leptin Prevents Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice: Involvement of Dopamine Receptors
por: Cordeiro, Rafaela Carneiro, et al.
Publicado: (2019)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Editorial: Community series in novel antipsychotics within and beyond clinical trials: symptom-based treatment of psychiatric disorders with D3-D2 partial agonists, volume II
por: Falkai, Peter, et al.
Publicado: (2023)

Kappa-Opioid Receptor Signaling in the Striatum as a Potential Modulator of Dopamine Transmission in Cocaine Dependence
por: Trifilieff, Pierre, et al.
Publicado: (2013)

Human Autoantibodies Against N-Methyl-D-Aspartate Receptor Modestly Alter Dopamine D1 Receptor Surface Dynamics
por: Gréa, Hélène, et al.
Publicado: (2019)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

Striatal increase of dopamine receptor 2 density in idiopathic and syndromic mouse models of autism spectrum disorder
por: Chhabra, Stuti, et al.
Publicado: (2023)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

A Role for Accumbal Glycine Receptors in Modulation of Dopamine Release by the Glycine Transporter-1 Inhibitor Org25935
por: Lidö, Helga Höifödt, et al.
Publicado: (2011)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
por: Sonnenschein, Susan F., et al.
Publicado: (2020)

Post-Mortem Toxicology: A Systematic Review of Death Cases Involving Synthetic Cannabinoid Receptor Agonists
por: Giorgetti, Arianna, et al.
Publicado: (2020)

Dihydrocodeine/Agonists for Alcohol Dependents
por: Ulmer, Albrecht, et al.
Publicado: (2012)

The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice
por: Zaveri, Nurulain T., et al.
Publicado: (2018)

Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany
por: Reiners, Sven, et al.
Publicado: (2022)

Dopamine Rebound-Excitation Theory: Putting Brakes on PTSD
por: Lee, Jason C., et al.
Publicado: (2016)

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
por: Amato, Davide, et al.
Publicado: (2019)

Expression of Dopamine D(1−4) and Serotonin 5-HT(1A-3A) Receptors in Blood Mononuclear Cells in Schizophrenia
por: Wysokiński, Adam, et al.
Publicado: (2021)

Effects of 2-bromoterguride, a dopamine D(2) receptor partial agonist, on cognitive dysfunction and social aversion in rats
por: Tarland, Emilia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_p3g3th7s74ja3044maohbuitev